New Tinnitus Treatments: What the Research Actually Shows
By Dr. Layne Garrett, Au.D., FAAA, ABAC, CH-TM, CDP (About | YouTube | Podcast | LinkedIn)
Date Published: October 12, 2026
A patient sat across from me recently with a folder of printouts. One article said a tinnitus cure was two years away. Another said nothing could be done. A video claimed a new device could “reset” his brain. He asked which one he was supposed to believe. This article sorts the real research from the noise, and points to what’s already approved and sitting mostly unused.
Table of Contents
- Quick Answer
- Why Tinnitus Research Headlines Get Distorted
- How I Evaluate Any Tinnitus Research
- The Device Most Patients Know as the Susan Shore Device
- Three More Treatments Still Years From a Clinic
- Ebselen Is Not a General Tinnitus Treatment
- Why TMS Hasn’t Become a Standard Tinnitus Treatment
- The Tinnitus Treatment That’s Already FDA Approved: Lenire
- Getting Evidence-Based Tinnitus Care Along the Wasatch Front
- FAQ
Quick Answer
No tinnitus-specific cure is close to a clinic in 2026. A few programs are genuinely promising. One headline-grabbing device already has real trial data behind it. One treatment researchers already tried has stalled out. None of that changes what’s true today. An FDA-authorized tinnitus device already exists and meets rigorous clinical guideline standards. Most patients researching “new tinnitus treatments” have never heard of it. This article is about what’s actually in the 2026 pipeline and how far off each one really is — and knowing the difference between years-away research and available-today treatment is the entire point.
Why Tinnitus Research Headlines Get Distorted
By the time a tinnitus study reaches YouTube or a Facebook share, it’s usually gone through a game of telephone.
A trial with 99 patients becomes “73.” A drug called ebselen becomes something that sounds like a Greek letter. A finished trial for one condition gets reported as if it treats tinnitus broadly.
The biggest problem usually isn’t that the research is false. It’s that the condition being studied, the stage of the research, or the strength of the results gets lost in translation.
I’ve treated tinnitus along the Wasatch Front for more than twenty years. I see patients that spend real emotional energy decoding headlines about research that’s years away.
Meanwhile, an evidence-based, FDA-authorized treatment may already be available a few miles from their house.
If you want the companion piece—the treatments the internet actively hypes that the research doesn’t back up—I’ve covered those separately in our look at the tinnitus treatments trending online.
This page is the forward-looking half: what’s coming, how strong the evidence is, and how far each treatment really is from a clinic.
Our comprehensive tinnitus guide covers the full range of what can drive or aggravate tinnitus. It’s useful context before sorting through what’s new.
How I Evaluate Any Tinnitus Research
Three questions cut through most of the hype:
- What phase is the trial in?
- How many patients were enrolled?
- Is this animal data or human data?
Apply that filter and tinnitus research headlines start to look very different.
A Phase 1 study in a small group of people is not the same thing as a large clinical trial. Animal research can be important, but it does not mean a treatment is ready for patients. And a study on sudden hearing loss should not be reported as if it proves a treatment works for tinnitus in general.
That simple three-question filter catches a surprising number of accuracy problems.
It also helps separate promising science from treatment decisions you can actually make today.
The Device Most Patients Know as the Susan Shore Device
Most patients know it as the Susan Shore device. Its actual name is Auricle, developed by Dr. Susan Shore and her research team at the University of Michigan.
Auricle uses bimodal stimulation, pairing precisely timed sound with mild electrical stimulation. The approach is designed for somatic tinnitus: tinnitus that changes in pitch or loudness when you move your jaw, neck, or other parts of the body.
The trial data is real and genuinely promising. In the 2023 JAMA Network Open study, researchers enrolled 99 patients and reported meaningful improvement with targeted auditory-somatosensory stimulation.
But here’s the part that matters if you’re looking for treatment today: Auricle is not FDA-authorized, it is not commercially available as of this writing, and no release date has been announced.
That makes the Susan Shore device promising research, not a treatment you can get right now. I don’t tell patients to wait on it when evidence-based options are already available.
If you want the full picture, including the trial details and where the research stands today, I’ve written a dedicated breakdown of Susan Shore’s research.
Three Tinnitus Treatments Still Years From the Clinic
A few other research programs come up often enough that they’re worth naming. Each is earlier-stage than the headlines sometimes make it sound.
AC102 is a drug being developed by the German company AudioCure. A single dose is delivered into the middle ear. In preclinical research, AC102 restored damaged connections between the inner ear and auditory nerve and reduced tinnitus-related behavior after acoustic trauma.
That’s promising, but it’s still animal data. AudioCure’s human Phase 2 AC102 program is focused on sudden sensorineural hearing loss, not tinnitus as a standalone condition. A dedicated human tinnitus trial has not yet established whether AC102 can reduce tinnitus in people.
Gateway Biotechnology has several hearing and tinnitus programs at different stages of development. Its GW-TT1 program focuses on noise-induced hearing loss, while its tinnitus-specific pipeline includes GW-TT2, an intranasal drug-delivery approach, and GW-TT5, an early gene-therapy program. Gateway’s current research pipeline shows just how early those tinnitus programs still are.
There is also small academic research looking at forms of vagus nerve stimulation for tinnitus. Those approaches remain experimental and aren’t close to routine clinical care.
Some of this is genuinely exciting science. None of it gives someone with tinnitus a treatment they can walk into a clinic and receive today.
That gap between “in development” and “available” is exactly where hype tends to fill in the blanks.
Ebselen Is Not a General Tinnitus Treatment
One correction comes up often enough that it’s worth clearing up. Some people remember this drug by a name that sounds like “Epsilon.” The actual drug is ebselen, also known as SPI-1005.
The important part isn’t the name. It’s the condition being studied.
Tinnitus is one of the common symptoms of Meniere’s disease, along with vertigo and fluctuating hearing loss. SPI-1005 is being studied as a treatment for Meniere’s disease, not as a general treatment for tinnitus.
The completed Phase 3 STOPMD-3 trial enrolled 220 adults with Meniere’s disease. SPI-1005 has also received FDA Breakthrough Therapy Designation for treating hearing loss in patients with Meniere’s disease, and a second Phase 3 open-label study has finished enrolling.
If you don’t have Meniere’s disease, this isn’t your drug.
That’s not a knock on the research. It’s real, and it’s moving forward. But this is a good example of how a legitimate study involving patients who may have tinnitus can turn into a headline that makes the treatment sound relevant to everyone with tinnitus.
It isn’t. Ebselen is being developed for Meniere’s disease, not tinnitus in general.
Why TMS Hasn’t Become a Standard Tinnitus Treatment
Transcranial magnetic stimulation, or TMS, is a real medical technique that uses magnetic pulses aimed at specific areas of the brain. Tinnitus studies typically involve a series of treatment sessions over several weeks.
The research has shown some short-term benefit, but durability remains the problem.
A 2025 meta-analysis of randomized controlled trials pooled data from more than 1,100 patients with chronic subjective tinnitus. It found improvement on some tinnitus measures shortly after treatment, but the benefit was not consistently maintained over time.
That matters because a treatment that helps briefly but does not produce durable improvement is hard to justify as routine tinnitus care.
The AAO-HNS Clinical Practice Guideline for Tinnitus recommends against routine use of TMS for patients with persistent, bothersome tinnitus.
I don’t build treatment plans around TMS today, and I won’t unless better evidence shows that the results last.
TMS is real. The research is real. The durability just isn’t there yet.
The Tinnitus Treatment That’s Already FDA Approved: Lenire
After all that research still years away, here’s the part many patients don’t realize: Lenire is an FDA-approved tinnitus treatment that’s already available today.
In March 2023, the FDA granted Lenire De Novo approval, creating a new Class II device category for combined acoustic and electrical stimulation for the relief of tinnitus. Lenire uses bimodal neuromodulation, combining sound through headphones with mild electrical stimulation of the tongue.
The pivotal TENT-A3 trial published in Nature Communications found clinically meaningful improvement in a substantial proportion of appropriately selected patients with moderate or worse tinnitus.
I won’t re-run all of the numbers here because we already cover them in detail on our Lenire tinnitus treatment page and in our deeper look at what the Lenire evidence actually shows, including the trial data and candidacy criteria.
The difference is that Lenire has already crossed the line from research into a tinnitus treatment patients can actually receive.
Lenire also isn’t the whole tinnitus treatment picture.
The AAO-HNS Clinical Practice Guideline for Tinnitus recommends a hearing aid evaluation for patients with hearing loss and persistent, bothersome tinnitus and recommends cognitive behavioral therapy for appropriate patients. It also recommends against routinely using treatments such as antidepressants, anticonvulsants, dietary supplements, and TMS specifically to treat persistent, bothersome tinnitus.
Ginkgo biloba is probably the supplement patients ask me about most, so I’ve also written about what the research actually shows about ginkgo and tinnitus.
Most clinics aren’t built around a full tinnitus treatment pathway. Ours is.
Every hearing aid fitting is verified with Real Ear Measurement. My Tinnitus Therapy combines CBT-based coaching with sound therapy, and we also offer Lenire for patients who are appropriate candidates.
For patients in Utah, Lenire is available through Timpanogos Hearing & Tinnitus as part of a broader evidence-based tinnitus treatment plan.
You don’t need to wait for a headline. You need to know which evidence-based options make sense for your tinnitus today.
Check Your Tinnitus Severity
Answer a few quick questions to see how much tinnitus may be affecting your daily life and which next step may make the most sense.
Where to Get Evidence-Based Tinnitus Treatment in Utah
If you’re in Utah and trying to decide what to do now, the next step is a proper tinnitus evaluation—not waiting for the next research headline.
We provide comprehensive tinnitus evaluations at three Wasatch Front locations serving both Utah County and Salt Lake County.
In Utah County, our American Fork clinic serves patients from American Fork, Lehi, Pleasant Grove, Orem, Provo, and surrounding communities. Our Spanish Fork clinic serves patients throughout southern Utah County including Payson, and Springville.
In Salt Lake County, our South Jordan tinnitus clinic serves patients from South Jordan, Sandy, Riverton, Herriman, West Jordan, Draper, and the surrounding southwest valley.
Every tinnitus evaluation starts with your hearing and your history, not a product. We look at your symptoms, hearing test results, possible contributing factors, and which evidence-based treatment options actually fit your situation.
After twenty years treating tinnitus along the Wasatch Front, I’ve learned that the right treatment plan often starts by figuring out which problem we’re actually trying to solve.
Timpanogos Hearing & Tinnitus has been recognized as Best of State in Auditory Services 15 times. We’re also one of a small number of Lenire Preferred Provider clinics in the United States and the only provider serving patients across Utah County and Salt Lake County.
When You’re Ready to Find Out Where You Stand
Schedule a consultation. We’ll evaluate your tinnitus and tell you honestly which options are worth considering now and which research developments are still worth watching.
Or call us at (385) 503-8052 to speak with our team directly.
If you want to keep digging into the research first, visit our Learning Center for detailed tinnitus treatment and research breakdowns.
FAQ
No single tinnitus cure is close to being available in a clinic in 2026. Several research programs are genuinely promising, including the Susan Shore device, but none has reached the point where patients can simply schedule treatment. Evidence-based options already available today include hearing aids when hearing loss is present, CBT-based tinnitus care, sound therapy, and Lenire for appropriate candidates.
The device many patients call the Susan Shore device is called Auricle. It uses targeted auditory-somatosensory stimulation for somatic tinnitus. The 2023 JAMA Network Open trial reported promising results, but Auricle is not FDA approved and is not commercially available as of this writing.
TMS has shown some short-term improvement in tinnitus studies, but the benefit has not been consistently durable. A 2025 meta-analysis found improvement on some measures, while the AAO-HNS tinnitus guideline recommends against routine TMS treatment for persistent, bothersome tinnitus.
Yes. Lenire received FDA De Novo approval in March 2023 and is available as a tinnitus treatment for appropriate candidates. The pivotal TENT-A3 trial published in Nature Communications reported clinically meaningful improvement in a substantial proportion of treated patients.
Start with a proper tinnitus evaluation rather than waiting for a future treatment. A full evaluation can identify hearing loss, possible contributing factors, and whether current options such as hearing aids, CBT-based care, sound therapy, or Lenire make sense for your specific situation.
Timpanogos Hearing & Tinnitus provides evidence-based tinnitus evaluations at our American Fork and Spanish Fork clinics in Utah County and our South Jordan clinic in Salt Lake County. Each evaluation looks at your hearing, tinnitus history, possible contributing factors, and which proven treatment options are appropriate for you.
About the Author
Dr. Layne Garrett, Au.D., FAAA, ABAC, CH-TM, CDP is the founder of Timpanogos Hearing & Tinnitus, with clinic locations in American Fork, Spanish Fork, and South Jordan, Utah. Over 20 years, he has specialized in tinnitus management, helping thousands of patients along the Wasatch Front. Timpanogos Hearing & Tinnitus has been recognized as Best of State in Auditory Services 15 times and is one of only 14 Lenire Preferred Providers in the United States. His practice emphasizes patient education over sales-driven care.
Reviewed/Edited By
Reviewed/Edited by: Dr. Layne Garrett, Au.D., FAAA, ABAC, CH-TM, CDP Date: Ocboter 12, 2026
